Microlin Bio is an emerging therapeutics company focusing on microRNA and its role in oncology.
MicroRNAs are recently discovered naturally-occurring RNA molecules (composed of 19 to 25 nucleotides) that do not encode proteins but instead regulate gene expression and various biological pathways. The improper balance of microRNAs is believed to be linked to many diseases, including cancer. We believe that microRNAs represent a new class of diagnostics and therapeutics that may be more effective in the treatment of cancer, with the potential for mitigated side effects in comparison with conventional small molecule drugs or biologics.
We have entered into agreements with the Ohio State Innovation Foundation, an affiliate of the Ohio State University, to exclusively license a portfolio of approximately 100 issued and pending patents and patent applications covering numerous microRNAs and a novel delivery technology for potential use in the development of our therapeutic product candidates.
We believe that we will build a strong position in the microRNA field, with not only a strong intellectual property portfolio, but also with a management team, board of directors and scientific advisory board with the experience and expertise in early stage biotechnology, therapeutic development, nanoparticle delivery and microRNA biology to maximize the potential of our company and our intellectual property.
Watch the video below to learn more about microRNAs: